DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Omaxe Limited — Product launch (Sub-para 3-Para B)

NSE 4 hrs ago·18 Aug 2026, 1:04 pm

Omaxe

Omaxe Limited has announced the launch of a new product line, a development that the company has formally communicated to the stock exchanges. This initiative marks a strategic move to expand its market presence and diversify its offerings.

For investors, this news is significant as it signals the company's intent to drive future growth and potentially enhance its revenue streams. The success of this new product will be a key factor in evaluating the company's ability to execute its business strategy.

Investors should now monitor the market reception of the launch and the company's subsequent financial disclosures. Tracking sales performance and customer feedback will be crucial to understanding the long-term impact of this expansion.